Natural History of Oculo-Pharyngeal Muscular Dystrophy (OPMD) - Israel National OPMD Registry
NCT07146256 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300
Last updated 2025-08-28
Summary
The goal of this open prospective multi-disciplinary observational study of patients with OPMD at various stages of clinical manifestations is to explore the natural history of the disease in the Israeli population.
Conditions
- Oculopharyngeal Muscular Dystrophy (OPMD)
Interventions
- OTHER
-
Non-interventional observational study
No intervention will be studied
Sponsors & Collaborators
-
The non-profit organization for promotion of health and cure of OPMD
collaborator UNKNOWN -
Sheba Medical Center
lead OTHER_GOV
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-02-01
- Primary Completion
- 2030-01-31
- Completion
- 2030-01-31
Countries
- Israel
Study Locations
More Related Trials
-
Natural History Observational Study of MPS IIIa in SMC
NCT04918641 ·Status: UNKNOWN
-
Natural History Study of Patients With MPS IIIA
NCT02746341 ·Status: COMPLETED
-
Natural History Study of Patients With Mucopolysaccharidosis Type IIIB (MPS IIIB, Sanfilippo Syndrome Type B)
NCT01509768 ·Status: COMPLETED
-
An 18-month Prospective Natural History Study to Gain Insight Into FSHD2 Pathophysiology and Disease Progression
NCT06079567 ·Status: RECRUITING ·Phase: NA
-
A Study of Patients With Sanfilippo Syndrome Type A (MPS IIIA)
NCT01047306 ·Status: COMPLETED
-
Ophthalmic Manifestations of Patients With Mucopolysaccharidosis
NCT04770415 ·Status: UNKNOWN
-
The Natural History Study of Patients With Sanfilippo Disease(s) (MPS3)
NCT05705674 ·Status: RECRUITING
-
PREPL in Health and Disease
NCT02263781 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Respiratory Cathepsins, Proteases Inhibitors and Glycosaminoglycans (GAG) in Mucopolysaccharidosis
NCT04112602 ·Status: COMPLETED
-
Understanding Fabry Disease Therapy Choices Through the Eyes of the Patients
NCT04804566 ·Status: COMPLETED
-
A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of FCFD4514S in Patients With Geographic Atrophy
NCT00973011 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I
NCT00912925 ·Status: COMPLETED ·Phase: PHASE3
-
Long Term Follow-up on Menkes Disease Patients
NCT04337684 ·Status: ACTIVE_NOT_RECRUITING
-
Clinical Characterization on PDE6A-related Retinitis Pigmentosa in Preparation to a Gene Therapy Trial
NCT02759952 ·Status: COMPLETED
-
Longitudinal Assessment of Atypical Tripeptidyl Peptidase 1 Enzyme Deficiency Patients
NCT04098211 ·Status: ACTIVE_NOT_RECRUITING
-
Carotid Structure and Function in MPS Syndromes: A Multicenter Study of the Lysosomal Disease Network
NCT01586871 ·Status: COMPLETED
-
New Imaging Technology to Assess Effect of Enzyme Replacment Therapy on Eye Disease Progession in Mucopolysacchardiosis
NCT02583152 ·Status: UNKNOWN
-
Mucopolysaccharidosis VII Disease Monitoring Program
NCT03604835 ·Status: RECRUITING
-
Safety, Tolerability, Pharmacokinetics (PK), and Activity of ATYR1940 in Participants With Muscular Dystrophy - Study Extension
NCT02531217 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)
NCT04635891 ·Status: RECRUITING
-
FSHD Molecular Characterization
NCT06096441 ·Status: TERMINATED
-
Extension Study of Intrathecal Enzyme Replacement for Cognitive Decline in MPS I
NCT02232477 ·Status: TERMINATED ·Phase: NA
-
A Study of GLWL-01 in Patients With Prader-Willi Syndrome
NCT03274856 ·Status: COMPLETED ·Phase: PHASE2
-
The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome
NCT00768820 ·Status: RECRUITING ·Phase: PHASE4
-
Natural History Study to Characterise the Course of Disease Progression in Participants With Mucopolysaccharidosis Type IIIB
NCT02293408 ·Status: TERMINATED